Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
This study has been completed.
Sponsor:
Antisense Pharma
Information provided by (Responsible Party):
Antisense Pharma
ClinicalTrials.gov Identifier:
NCT00844064
First received: February 12, 2009
Last updated: November 18, 2011
Last verified: November 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | November 2011 |
| Primary Completion Date: | November 2011 (Final data collection date for primary outcome measure) |